Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study

• Published in: European urology 2022-07, Vol.82 (1), p.12-19
• Main Authors: Hao, Shuang, Heintz, Emelie, Östensson, Ellinor, Discacciati, Andrea, Jäderling, Fredrik, Grönberg, Henrik, Eklund, Martin, Nordström, Tobias, Clements, Mark S.
• Format: Article
• Language: English
• Subjects: Biopsy; Cost-effectiveness; Magnetic resonance imaging; Medicin och hälsovetenskap; Microsimulation; Prostate cancer; Screening; Stockholm3; Sweden
• ISSN: 0302-2838; 1873-7560; 1873-7560
• DOI: 10.1016/j.eururo.2021.12.021

Compared with prostate-specific antigen (PSA) testing, the use of Stockholm3 at a reflex threshold of PSA ≥2 ng/ml for magnetic resonance imaging (MRI)-based screening reduced the use of MRI and biopsies by, respectively, 60% and 9% across a lifetime. This strategy is considered to be cost-effective in Sweden. Stockholm3 is a risk model that combines the prostate-specific antigen (PSA) test, other plasma protein biomarkers, single nucleotide polymorphisms, and clinical variables. The STHLM3-MRI study (NCT03377881) found that the Stockholm3 test with magnetic resonance imaging (MRI) and combined targeted and systematic biopsies maintained the sensitivity for clinically significant cancers, and reduced the number of benign biopsies and clinically insignificant cancers. To assess the cost-effectiveness of MRI-based screening for prostate cancer using either Stockholm3 as a reflex test or PSA alone. A cost-utility analysis was performed from a lifetime societal perspective using a microsimulation model for men aged 55–69 yr in Sweden. Test characteristics were estimated from the STHLM3-MRI study. No screening and three quadrennial screening strategies, including either PSA ≥3 ng/ml or Stockholm3 with reflex test thresholds of PSA ≥1.5 or 2 ng/ml as criteria for referral to MRI, were performed, and those who were MRI positive had combined targeted and systematic biopsies. Predictions included the number of tests, cancer incidence and mortality, costs, and quality-adjusted life-years. Uncertainties in key parameters were assessed using sensitivity analyses. Compared with no screening, the screening strategies were predicted to reduce prostate cancer deaths by 7–9% across a lifetime. The use of Stockholm3 with PSA ≥2 ng/ml resulted in a 60% reduction in MRI compared with screening using PSA. This Stockholm3 strategy was cost-effective with a probability of 70% at a cost-effectiveness threshold of €47 218 (500 000 Swedish Kronor). As a potential limitation, the economic perspective was specific to Sweden. Screening with the Stockholm3 test at a reflex threshold of PSA ≥2 ng/ml and MRI was predicted to be cost-effective in Sweden. The Stockholm3 test with image-based screening may reduce screening-related harms and costs, while maintaining the health benefits from early detection of prostate cancer.